Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Tarun K. Garg, PhD, Ricky D Edmondson, PhD, Shweta S. Chavan, PhD, Katie Stone, BS, Justin M Stivers, Jessica I Warden, Veronica Macleod, Charles M Skinner, Joshuah D Lingo, Amy D Greenway, Junaid Khan, Donald Johann, MD MS, Christoph Heuck, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD

Blood (2015) 126 (23): 2990.

https://doi.org/10.1182/blood.V126.23.2990.2990

Published: 2015

Journal Articles

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Meera Mohan, Rohan Samant, Larry J Suva, Corey O Montgomery, Daisy V. Alapat, MD, Roy Morello, Frits van Rhee, MD PhD, Sarah Waheed, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Christoph Heuck, MD, Yogesh Jethava, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Maurizio Zangari, MD

Blood (2015) 126 (23): 4193.

https://doi.org/10.1182/blood.V126.23.4193.4193

Published: 2015

Journal Articles

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Blood (2015) 126 (23): 20.

https://doi.org/10.1182/blood.V126.23.20.20

Published: 2015

Journal Articles

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

Blood (2015) 126 (23): 369.

https://doi.org/10.1182/blood.V126.23.369.369

Published: 2015

Journal Articles

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Blood (2015) 126 (23): 372.

https://doi.org/10.1182/blood.V126.23.372.372

Published: 2015

Journal Articles

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Maurizio Zangari, MD, Caleb K Stein, MS, Shmuel Yaccoby, PhD, Donghoon Yoon, PhD, Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Donald Johann, MD MS, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3409.

https://doi.org/10.1182/blood.V124.21.3409.3409

Published: 2014

Journal Articles

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

Christoph Heuck, MD, Donald Johann, MD MS, Brian A Walker, PhD, Caleb K Stein, MS, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Ruslana Tytarenko, Phillip Farmer, Ryan Williams, Siraj Ali, MDPhD, Phil J Stephens, PhD, Vincent A. Miller, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3418.

https://doi.org/10.1182/blood.V124.21.3418.3418

Published: 2014

Journal Articles

Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma

Jeffrey Sawyer, PhD, Erming Tian, PhD, Christoph Heuck, MD, Donald Johann, MD MS, Joshua Epstein, DSc, Charles Swanson, Janet Lukacs, Regina Lichti Binz, Gael Sammartino, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 725.

https://doi.org/10.1182/blood.V124.21.725.725

Published: 2014

Journal Articles

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Frits van Rhee, MD PhD, Alan Mitchell, Christoph Heuck, MD, Monica Grazziutti, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 1199.

https://doi.org/10.1182/blood.V124.21.1199.1199

Published: 2014

Journal Articles

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Alan Mitchell, Donald Johann, MD MS, Kelly Robbins, Ryan K Van Laar, PhD, Siraj Ali, MDPhD, Vincent A. Miller, MD, Clyde Bailey, Jeffery Sawyer, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 4775.

https://doi.org/10.1182/blood.V124.21.4775.4775

Published: 2014

Journal Articles

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

Adam Rosenthal, Christoph Heuck, MD, Aziz Bakhous, M.D., Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Donald Johann, MD, MS, Joshua Epstein, DSc, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1870.

https://doi.org/10.1182/blood.V122.21.1870.1870

Published: 2013

Journal Articles

Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis

Tarun K. Garg, PhD, Ricky D Edmondson, PhD, Shweta S. Chavan, PhD, Junaid Khan, PhD, Susann Szmania, BS, Justin Stivers, BS, Veronica Macleod, BS, Katie Stone, BS, Emily Woods, BS, Donald Johann, MD, MS, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2013) 122 (21): 3105.

https://doi.org/10.1182/blood.V122.21.3105.3105

Published: 2013

Journal Articles

Leveraging The Old With The New: Exploring and Integrating Historic Microarray Studies With Next Generation Sequencing For Multiple Myeloma

Michael A Bauer, PhD, Erich A Peterson, PhD, Shweta S. Chavan, PhD, Daniel Pollock, BS, Christoph Heuck, MD, Donald Johann, MD, MS

Blood (2013) 122 (21): 3122.

https://doi.org/10.1182/blood.V122.21.3122.3122

Published: 2013

Journal Articles

Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions

Bart Barlogie, MD, PhD, Emily Hansen, MS, Sarah Waheed, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Joshua Epstein, DSc

Blood (2013) 122 (21): 3123.

https://doi.org/10.1182/blood.V122.21.3123.3123

Published: 2013

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

Journal Articles

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

Donald Johann, MD, MS, Pingping Qu, PhD, Rachael Sexton, Antje Hoering, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Frits van Rhee, MD, PhD, Saad Z Usmani, MD FACP, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 3953.

https://doi.org/10.1182/blood.V120.21.3953.3953

Published: 2012

Journal Articles

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Saad Z Usmani, MD FACP, Sarah Waheed, MD, Alan Mitchell, John Crowley, PhD, Antje Hoering, Nathan M Petty, Joshua Epstein, DSc, Christoph Heuck, MD, Shmuel Yaccoby, PhD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2012) 120 (21): 2910.

https://doi.org/10.1182/blood.V120.21.2910.2910

Published: 2012

Journal Articles

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols – Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS)

Christoph Heuck, MD, Pingping Qu, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Madhav V. Dhodapkar, MD, Joshua Epstein, DSc, Qing Zhang, PhD, Donald Johann, MD, MS, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 198.

https://doi.org/10.1182/blood.V120.21.198.198

Published: 2012

NARROW

Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis

Leveraging The Old With The New: Exploring and Integrating Historic Microarray Studies With Next Generation Sequencing For Multiple Myeloma

Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols – Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only